- Home
- Software Solutions
- Resources
- Corporate
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesilate in Patients With Inoperable or Recurrent Breast Cancer
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 500 | |
Additional information about NCT01463891.